122 related articles for article (PubMed ID: 38915065)
1. Impact of RA treatment strategies on lipids and vascular inflammation in rheumatoid arthritis: a secondary analysis of the TARGET randomized active comparator trial.
Liao KP; Rist P; Giles J; Santacroce L; Connelly MA; Glynn RJ; Ridker P; Tawakol A; Bathon J; Solomon DH
Arthritis Res Ther; 2024 Jun; 26(1):123. PubMed ID: 38915065
[TBL] [Abstract][Full Text] [Related]
2. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
[TBL] [Abstract][Full Text] [Related]
3. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial.
Navarro-Millán I; Charles-Schoeman C; Yang S; Bathon JM; Bridges SL; Chen L; Cofield SS; Dell'Italia LJ; Moreland LW; O'Dell JR; Paulus HE; Curtis JR
Arthritis Rheum; 2013 Jun; 65(6):1430-8. PubMed ID: 23460074
[TBL] [Abstract][Full Text] [Related]
4. Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis.
Solomon DH; Giles JT; Liao KP; Ridker PM; Rist PM; Glynn RJ; Broderick R; Lu F; Murray MT; Vanni K; Santacroce LM; Abohashem S; Robson PM; Fayad Z; Mani V; Tawakol A; Bathon J;
Ann Rheum Dis; 2023 Mar; 82(3):324-330. PubMed ID: 36450449
[TBL] [Abstract][Full Text] [Related]
5. The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical Trial (ESCoRT study).
Zhao J; Zhou W; Wu Y; Ji P; Yang L; Yan X; Zhang Z
BMC Med Inform Decis Mak; 2021 Mar; 21(1):83. PubMed ID: 33663487
[TBL] [Abstract][Full Text] [Related]
6. Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial.
Charles-Schoeman C; Yin Lee Y; Shahbazian A; Wang X; Elashoff D; Curtis JR; Navarro-Millán I; Yang S; Chen L; Cofield SS; Moreland LW; Paulus H; O'Dell J; Bathon J; Louis Bridges S; Reddy ST
Arthritis Rheumatol; 2017 Jan; 69(1):46-57. PubMed ID: 27483410
[TBL] [Abstract][Full Text] [Related]
7. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.
Moreland LW; O'Dell JR; Paulus HE; Curtis JR; Bathon JM; St Clair EW; Bridges SL; Zhang J; McVie T; Howard G; van der Heijde D; Cofield SS;
Arthritis Rheum; 2012 Sep; 64(9):2824-35. PubMed ID: 22508468
[TBL] [Abstract][Full Text] [Related]
8. Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis.
Sauer BC; Teng CC; Tang D; Leng J; Curtis JR; Mikuls TR; Harrison DJ; Cannon GW
Arthritis Care Res (Hoboken); 2017 Mar; 69(3):313-322. PubMed ID: 27273801
[TBL] [Abstract][Full Text] [Related]
9. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.
Gabay C; McInnes IB; Kavanaugh A; Tuckwell K; Klearman M; Pulley J; Sattar N
Ann Rheum Dis; 2016 Oct; 75(10):1806-12. PubMed ID: 26613768
[TBL] [Abstract][Full Text] [Related]
10. Serum survivin predicts responses to treatment in active rheumatoid arthritis: a post hoc analysis from the SWEFOT trial.
Levitsky A; Erlandsson MC; van Vollenhoven RF; Bokarewa MI
BMC Med; 2015 Sep; 13():247. PubMed ID: 26420684
[TBL] [Abstract][Full Text] [Related]
11. Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial.
Charles-Schoeman C; Wang X; Lee YY; Shahbazian A; Navarro-Millán I; Yang S; Chen L; Cofield SS; Moreland LW; O'Dell J; Bathon JM; Paulus H; Bridges SL; Curtis JR
Arthritis Rheumatol; 2016 Mar; 68(3):577-86. PubMed ID: 26606398
[TBL] [Abstract][Full Text] [Related]
12. Therapies for active rheumatoid arthritis after methotrexate failure.
O'Dell JR; Mikuls TR; Taylor TH; Ahluwalia V; Brophy M; Warren SR; Lew RA; Cannella AC; Kunkel G; Phibbs CS; Anis AH; Leatherman S; Keystone E;
N Engl J Med; 2013 Jul; 369(4):307-18. PubMed ID: 23755969
[TBL] [Abstract][Full Text] [Related]
13. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
Karlsson JA; Neovius M; Nilsson JÅ; Petersson IF; Bratt J; van Vollenhoven RF; Ernestam S; Geborek P
Ann Rheum Dis; 2013 Dec; 72(12):1927-33. PubMed ID: 23196701
[TBL] [Abstract][Full Text] [Related]
14. Antirheumatic therapy is associated with reduced complement activation in rheumatoid arthritis.
Nguyen THP; Hokstad I; Fagerland MW; Mollnes TE; Hollan I; Feinberg MW; Hjeltnes G; Eilertsen GØ; Mikkelsen K; Agewall S
PLoS One; 2022; 17(2):e0264628. PubMed ID: 35213675
[TBL] [Abstract][Full Text] [Related]
15. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
16. A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure.
Hambardzumyan K; Saevarsdottir S; Forslind K; Petersson IF; Wallman JK; Ernestam S; Bolce RJ; van Vollenhoven RF
Arthritis Rheumatol; 2017 May; 69(5):953-963. PubMed ID: 27992691
[TBL] [Abstract][Full Text] [Related]
17. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
[TBL] [Abstract][Full Text] [Related]
18. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial.
O'Dell JR; Curtis JR; Mikuls TR; Cofield SS; Bridges SL; Ranganath VK; Moreland LW;
Arthritis Rheum; 2013 Aug; 65(8):1985-94. PubMed ID: 23686414
[TBL] [Abstract][Full Text] [Related]
19. Sustained Remission in Patients With Rheumatoid Arthritis Receiving Triple Therapy Compared to Biologic Therapy: A Swedish Nationwide Register Study.
Källmark H; Einarsson JT; Nilsson JÅ; Olofsson T; Saxne T; Geborek P; C Kapetanovic M
Arthritis Rheumatol; 2021 Jul; 73(7):1135-1144. PubMed ID: 33682353
[TBL] [Abstract][Full Text] [Related]
20. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review.
Mary J; De Bandt M; Lukas C; Morel J; Combe B
J Rheumatol; 2017 Jun; 44(6):773-779. PubMed ID: 28412710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]